Long-Term Follow Up Study of Subjects Previously Administered HMI 102

Last updated: June 28, 2022
Sponsor: Homology Medicines, Inc
Overall Status: Active - Enrolling

Phase

N/A

Condition

Phenylketonuria

Treatment

N/A

Clinical Study ID

NCT04348708
HMI-102-102
  • Ages 18-55
  • All Genders

Study Summary

An Open-Label, Long-Term Follow Up Study of Safety and Efficacy in PKU Subjects with PAH Deficiency Previously Administered HMI 102

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Subject was previously administered HMI 102.
  • Subject is able to understand the purpose and risks of the study and is willing toprovide informed consent.
  • Subject is able to comply with all study procedures and long-term follow-up.

Exclusion

Exclusion Criteria:

  • Participation in the study is not in the subject's best interest, in the opinion ofthe Investigator.

Study Design

Total Participants: 21
Study Start date:
August 19, 2020
Estimated Completion Date:
December 01, 2026

Study Description

This Long-Term Follow Up Study will evaluate the safety and efficacy of PKU Subjects with PAH Deficiency Previously Administered HMI 102. Subjects will have already received a single dose of HMI-102 administered intravenously

Connect with a study center

  • Boston Children's Hospital

    Boston, Massachusetts 02115
    United States

    Site Not Available

  • Icahn School of Medicine at Mount Sinai

    New York, New York 10029
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.